Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emerson, S. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Emerson, S. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

Blood, 1 May 2001, Vol. 97, No. 9, pp. 2533-2534

Punching holes in GVHD and GVL

T lymphocytes contained within an allogeneic stem cell transplant for leukemia are a force for both good and evil. T cells significantly decrease the incidence of disease relapse by killing leukemic cells (graft-versus-leukemia effect, or GVL) while simultaneously causing often life-threatening graft-versus-host disease (GVHD). Whether these processes are fundamentally different enough that GVHD can be abrogated while GVL is preserved, by such approaches as depletion of T-cell subset and manipulation of cytokines thought to induce (eg, TNF) or inhibit (eg, IL-11) the inflammatory GVHD response, has been uncertain. Schmaltz and colleagues (page 2886) now show that distinct T-cell effector pathways can preferentially cause GVL, but not GVHD. Using a mouse parent-into-F1 bone marrow transplantation model, congenic strains deficient in FasL or the granule protein perforin, and 2 myeloid leukemic cell lines, they find that the Fas/FasL pathway is critical to the appearance of GVHD but not to antileukemic T-cell killing. Even though both leukemic lines express Fas and can be killed by cell lines expressing FasL in vitro, GVL does not require Fas/FasL in vivo. Perforin-deficient T cells, in contrast, provide little detectable GVL but still cause GVHD.

These findings, if validated in other stem cell transplantation models, suggest that therapies aimed at blocking the Fas/FasL pathway after T-cell-replete stem cell transplantation might provide sufficient therapeutic index to blunt GVHD without preventing GVL. Whether such treatments would need to be continued for months or years and whether there would be any unexpected infectious or dysplastic side effects caused by blockade of T-cell FasL surveillance would need to be explored as well. Schmaltz and colleagues' studies now illuminate the effector phase of the immune response as a novel opportunity for decisive interventions in the battle to increase the safety and efficacy of stem cell transplantations.


---Stephen G. Emerson
University of Pennsylvania


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emerson, S. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Emerson, S. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020